ERAS-0015 / Erasca, Guangzhou JOYO Pharma - LARVOL DELTA

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 (GlobeNewswire) - "Greater than 90%, mean, tumor-growth inhibition versus vehicle controls (p < 0.001). Marked reduction in metastatic burden in the liver and peritoneum; Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of EMT markers; Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting the potential for lower chemotherapy doses with improved efficacy; Median overall survival extension of more than 2.5-fold in treated animals compared with controls...These results complement previously reported >85% tumor-growth inhibition data and peer-reviewed findings on PRP’s effects on PDAC fibroblasts."

Preclinical • Pancreatic Ductal Adenocarcinoma

Combination of ERAS-0015 and ERAS-4001 Targets Active and Inactive KRAS and Displays Synergy in Nonclinical KRAS G12X-Driven Models (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Oncology • KRAS

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium (The Manila Times) - "Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial...Poster presentation to share nonclinical combination data of ERAS-0015 and ERAS-4001 demonstrating synergy in KRAS G12X-driven models."

First-in-human • P1 data • Preclinical • Pancreatic Ductal Adenocarcinoma

Preliminary safety, pharmacokinetics, and efficacy of ERAS-0015: Results from the AURORAS-1 first-in-human trial (EORTC-NCI-AACR 2026) - "Abstract will be available on the day of the presentation"

Clinical • First-in-human • P1 data • PK/PD data • Oncology

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma (The Manila Times) - "In July 2026, Erasca reported updated preliminary data from the AURORAS-1 Phase 1 trial in the U.S. demonstrating encouraging clinical activity, including a 57% uORR8wk in patients with second-line or later (2L+) KRAS G12X pancreatic ductal adenocarcinoma (PDAC) receiving ERAS-0015 monotherapy at the recommended dose for expansion (RDE) of 32 mg once daily....Additional data from the monotherapy expansion and combination dose escalation cohorts, including the panitumumab combination, are expected in the first half of 2027."

Fast track • P1 data • Pancreatic Ductal Adenocarcinoma

Tango Therapeutics...Provides Business Highlights (GlobeNewswire) - "Present Phase 1/2 data of vopimetostat in combination with RAS(ON) inhibitors at the 2026 ESMO Congress in Madrid, Spain from October 23-27, 2026; Finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pancreatic cancer in 2H 2026; Disclose vopimetostat lung cancer monotherapy data in 2H 2026; Release initial TNG456 data in glioblastoma and other cancers in 2H 2026; Initiate Phase 1/2 vopimetostat + ERAS-0015 (Erasca) combination study in 2H 2026."

Clinical protocol • New P1/2 trial • P1/2 data • Glioblastoma • Pancreatic Cancer

Key Upcoming Milestones - AURORAS-1 to -3: Trials for ERAS-0015 (potential best-in-class pan-RAS molecular glue) (GlobeNewswire) - "(i) Phase 1 monotherapy expansion data expected in the first half of 2027; (ii) Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027; (iii) Potentially registration-enabling trial in 2L+ NSCLC expected to initiate in the first half of 2027; (iv) Phase 3 pivotal trial in 1L PDAC expected to initiate in 2027; (v) Phase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028."

New P3 trial • P1 data • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

ERAS-0015: “Encouraging preliminary ERAS-0015 efficacy data in patients with 2L+ KRAS G12X PDAC: 57% uORR at 32 mg observed”; Pancreatic ductal adenocarcinoma (Erasca Biotech) - ERAS-0015 Preliminary Phase 1 Data Update

P1 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Erasca…announced updated preliminary Phase 1 data for its potentially best-in-class, pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors (GlobeNewswire) - "At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100%. Monotherapy has been generally well-tolerated at RDEs. Promising combination potential, including no DLTs, encouraging safety data, and clearance of first dose escalation combination cohort of ERAS-0015 (16 mg) with approved commercial dose of panitumumab. Additional ERAS-0015 monotherapy and combination data expected H1 2027, including panitumumab combination data."

P1 data • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

Accelerating Potentially Registration-Enabling Development Plans in Highest Value Indications (GlobeNewswire) - "(i) Initiate potentially registration-enabling trial in 2L+ NSCLC in 1H27; (ii) Initiate 1L PDAC Phase 3 pivotal trial in 2027; (iii) Initiate RASm NSCLC Phase 3 pivotal trial in 2H27-1H28."

New P3 trial • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

AURORAS-1: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=600 | Recruiting | Sponsor: Erasca, Inc. | N=200 ➔ 600

Enrollment change • First-in-human • Monotherapy • Oncology • Solid Tumor

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab) (GlobeNewswire) - "This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with RAS-mutant (RASm) solid tumors. Erasca is sponsoring the study, and Merck is supplying pembrolizumab at no cost."

Licensing / partnership • Solid Tumor

Tango Therapeutics…Provides Business Highlights (GlobeNewswire) - "Upcoming Expected Milestones: (i) Initial phase 1/2 safety and efficacy data from combination trial with vopimetostat + daraxonrasib, and vopimetostat + zoldonrasib (Revolution Medicines) in 2026; (ii) Vopimetostat monotherapy phase 1/2 clinical data lung cancer update in 2026; (iii) TNG456 monotherapy phase 1/2 trial initial safety and efficacy data in 2026' (iv) Initiate phase 1/2 vopimetostat + ERAS-0015 (Erasca) combination study 2H 2026."

New P1/2 trial • P1/2 data • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

Erasca Touts ’Eye-Popping’ ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference (TradingView) - "Lim said Erasca’s lead pan-RAS molecule, ERAS-0015, has shown differentiated early data, including response rates in non-small cell lung cancer that he described as 'eye-popping.' He cited response rates of 62% to 75% in the pharmacologically active dose range of 16 mg to 32 mg in non-small cell lung cancer, depending on the subgroup analyzed....Lim said Erasca has opened expansion cohorts at recommended doses for expansion of 24 mg and 32 mg and is enrolling non-small cell lung cancer patients at both doses. Once the company has roughly 20 patients in each expansion cohort, he said Erasca plans to package the data and discuss a registrational trial design with the U.S. Food and Drug Administration."

Clinical data • FDA event • Non Small Cell Lung Cancer

Research and Development (R&D) Highlights (The Manila Times) - "In April 2026, Erasca announced that dose escalation of ERAS-0015 in combination with anti-EGFR monoclonal antibody panitumumab was initiated in the first quarter of 2026 and that the monotherapy expansion cohorts for ERAS-0015 were initiated in the second quarter of 2026. Both of these milestones were completed ahead of the original second half of 2026 guidance...AURORAS-1: Phase 1 trial for ERAS-0015 (pan-RAS molecular glue) in patients with RAS-mutant solid tumors: Monotherapy expansion data expected in the first half of 2027; Combination dose escalation data planned for the first half of 2027...BOREALIS-1...Preliminary safety, tolerability, PK, and initial efficacy Phase 1 monotherapy data expected in the second half of 2026; Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027."

P1 data • Trial status • Solid Tumor

Key Upcoming and Completed Milestones (GlobeNewswire) - "(i) AURORAS-1: Phase 1 trial for ERAS-0015 (pan-RAS molecular glue) in patients with RAS-mutant solid tumors: Monotherapy expansion data and combination dose escalation data narrowed to an expected date of H1 2027; (ii) BOREALIS-1: Phase 1 trial for ERAS-4001 (pan-KRAS inhibitor) in patients with KRAS-mutant solid tumors: Preliminary Phase 1 monotherapy data expected in the second half of 2026; Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027."

P1 data • Trial status • Solid Tumor

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors (GlobeNewswire) - "The preliminary data are from Erasca’s ongoing AURORAS-1 Phase 1 dose escalation trial in the U.S. and the ongoing JYP0015M101 Phase 1 dose escalation trial....Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE. Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD. Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs."

P1 data • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma

RCZY-690: A tri-complex molecular glue pan-RAS (ON) inhibitor exhibiting best-in-class potential for RAS-addicted solid tumors (AACR 2026) - "Compared to RMC-6236 and ERAS-0015, it shows higher degree of preferential tumor distribution in mouse models. RCZY-690 demonstrates favorable PK/PD profiles, including more durable DUSP6 suppression than RMC-6236, alongside excellent in vivo tolerability and promising safety margins in preclinical toxicity studies. Taken together, these attributes position RCZY-690 as a promising pan-RAS(ON) inhibitor and support its advancement toward an Investigational New Drug (IND) filing planned for Q2 2026."

Oncology • Solid Tumor • DUSP6 • HRAS • KRAS • NRAS

ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumors (AACR 2025) - "ERAS-0015's roughly 8-20-fold higher binding affinity to cyclophilin A (CYPA) is thought to contribute to its higher in vitro cellular potency as well as favorable ADME and PK properties resulting in a longer residence time and greater exposure in tumor tissues as compared to RMC-6236. These favorable properties enabled ERAS-0015 to achieve comparable tumor growth inhibition (TGI) relative to RMC-6236 at 1/8th-1/10th the dose across multiple KRAS mutant CDX models irrespective of histology or specific mutation.ERAS-0015 demonstrated promising preclinical activity across multiple RAS mutant models supporting IND filing in 1H 2025."

Oncology • Solid Tumor • KRAS • RAS

Key Upcoming Milestones (GlobeNewswire) - "AURORAS-1 and JYP0015M101: Phase 1 monotherapy data from...China expected in the first half of 2026; Initiation of AURORAS-1 monotherapy expansion cohorts and combination dose escalation cohort planned for the second half of 2026; AURORAS-1 monotherapy expansion data and combination dose escalation data planned for 2027."

P1 data • Trial status • Solid Tumor

STAR: Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (clinicaltrials.gov) - P2 | N=210 | Recruiting | Sponsor: Guangzhou JOYO Pharma Co., Ltd | Phase classification: P1/2 ➔ P2

Phase classification • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • RAS

Erasca is advancing ERAS-0015 in the ongoing AURORAS-1 Phase 1 dose escalation trial in patients with RAS-mutant solid tumors with initial Phase 1 monotherapy data expected in the first half of 2026 (GlobeNewswire)

P1 data • Trial status • Solid Tumor

Erasca…announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will provide Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015 (GlobeNewswire) - "Under the terms of the ERAS-0015 license agreement, Erasca exercised its option to convert its territory to worldwide and is obligated to make a one-time payment to Joyo based on the stage of Joyo’s development program."

Licensing / partnership • Solid Tumor

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat (GlobeNewswire) - "This agreement will support a Phase 1/2 clinical trial evaluating ERAS-0015 in combination with vopimetostat in patients with MTAPdel pancreatic or MTAPdel RASm non-small cell lung cancer (NSCLC). Erasca will supply ERAS-0015 free of charge, and Tango will be the trial sponsor."

Commercial • New P1/2 trial • Non Small Cell Lung Cancer

Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 (GlobeNewswire)

P1 data • Solid Tumor